IN8bio Shares Soar Following Positive Data for Leukemia Treatment
Biopharmaceutical company, IN8bio, Inc. (Nasdaq: INAB), saw its share price rise by nearly 186% following the release of positive, new data from its Phase 1 clinical trial evaluating INB-100 in leukemia patients.
The data showed long-term complete remissions and elevated gamma-delta T cells in 100% of evaluable treated patients. Gamma-delta T cells possess unique properties, including the ability to differentiate between healthy and diseased tissue.
In8bio’s Phase 1 clinical trial showed that INB-100 treatment achieved durable 100% complete remission in treated patients, including high-risk acute myeloid leukemia patients and a patient with acute lymphoblastic leukemia.
The study also demonstrated that allogeneic gamma-delta T cell expansion and persistence continued up to 180 days post-treatment. This is the first-ever demonstration of this type of response in an allogeneic cellular therapy.
IN8bio’s trial is a dose-escalation trial of allogeneic derived gamma-delta T cells from matched related donors that have been expanded and activated and administered systemically to leukemia patients.
The trial’s primary endpoints included safety and tolerability, and secondary endpoints included rates of GvHD, relapse rate and overall survival.
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.